Improving Retreatment Success (IMPRESS)

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 7% of the time (96 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-07-17. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientsgreaterserumchemotherapystatus
  Phrases that lowered it: hiv infectedlabelartopentuberculosis
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 1/2 (raises risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 15.5% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Design: parallel (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports marked serious: 90.1% (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Sponsor's past trials: 3 (raises risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 391 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis NCT00864383 · started 2008 · scored riskier than 29% of active trials completed
• Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients NCT03338621 · started 2018 · scored riskier than 32% of active trials completed
• Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis NCT00728507 · started 2009 · scored riskier than 40% of active trials terminated
• TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens NCT02410772 · started 2016 · scored riskier than 27% of active trials completed
• An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis NCT02454205 · started 2015 · scored riskier than 11% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.